{
    "nct_id": "NCT04592874",
    "title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2024-09-16",
    "description_brief": "A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disease.",
    "description_detailed": "This is a phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 administered intravenously in participants with Early Alzheimer's Disease.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted biologic",
    "drug": [
        "AL002 (humanized monoclonal antibody targeting TREM2)"
    ],
    "placebo": [
        "Placebo (matching IV infusion)"
    ],
    "explanation_target": [
        "Reason: The trial tests AL002, an engineered humanized monoclonal antibody designed to bind and agonize TREM2 on microglia to enhance microglial signaling, phagocytosis and function \u2014 an approach intended to modify Alzheimer\u2019s disease biology rather than only treat symptoms. \ue200cite\ue202turn0search6\ue202turn0search2\ue201",
        "Act: Key extracted details \u2014 drug name AL002; drug type: investigational humanized IgG1 monoclonal antibody (TREM2 agonist); indication: early Alzheimer\u2019s disease; trial: INVOKE-2, randomized double-blind placebo-controlled Phase 2 with IV dosing every 4 weeks. These sources describe target engagement, mechanism (TREM2 activation/microglial modulation), and the Phase 2 design. \ue200cite\ue202turn0search0\ue202turn0search6\ue201",
        "Reflect: Classification check \u2014 AL002 is a biologic (monoclonal antibody) directly targeting an AD-related pathway (TREM2/microglial activation) with the intent to alter disease processes, so it fits the 'disease-targeted biologic' category. Supporting company/press summaries and trial registry descriptions concur. No indication AL002 is a small molecule, symptomatic cognitive enhancer, or purely neuropsychiatric symptom treatment. \ue200cite\ue202turn0search4\ue202turn0search3\ue201"
    ],
    "agent_type": "F) Inflammation",
    "explanation_agent": [
        "Reason: The investigational agent AL002 is a humanized monoclonal antibody that binds and agonizes TREM2 on microglia to enhance microglial signaling, phagocytosis and function \u2014 i.e., it directly modulates brain innate immune / microglial activity rather than targeting amyloid or tau. \ue200cite\ue202turn0search0\ue202turn0search2\ue201",
        "Act: Key extracted details \u2014 AL002: investigational humanized mAb (TREM2 agonist); indication: early Alzheimer\u2019s disease; Phase 2 INVOKE\u20112 randomized, double\u2011blind, placebo\u2011controlled with IV dosing every 4 weeks. The trial and mechanistic descriptions explicitly describe TREM2/microglial modulation (immune pathway). \ue200cite\ue202turn0search5\ue202turn0search0\ue201",
        "Reflect: TREM2 is a microglial/innate\u2011immune receptor and AL002\u2019s intended mechanism is to activate microglia and modulate neuroinflammation. This maps to CADRO category F) Inflammation (microglia/immune modulators). The program\u2019s publications and press releases also report target engagement and microglial pharmacodynamic effects, supporting this classification; there is no primary indication that AL002 is primarily amyloid\u2011 or tau\u2011directed or a multi\u2011target symptomatic therapy. \ue200cite\ue202turn0search6\ue202turn0search3\ue201",
        "Web search results (supporting sources):",
        "- Alector press release describing INVOKE\u20112 Phase 2 and AL002 as a TREM2 agonist designed to increase TREM2 signaling and enhance microglial function. \ue200cite\ue202turn0search0\ue201",
        "- Preclinical and first\u2011in\u2011human evaluation of AL002 (publication) describing AL002 as a TREM2\u2011activating antibody with evidence of target engagement and microglial effects. \ue200cite\ue202turn0search2\ue201",
        "- Alector press release / publication noting preclinical and Phase 1 data validating AL002 (TREM2 activating antibody) and its microglial biology. \ue200cite\ue202turn0search6\ue201",
        "- INVOKE\u20112 clinical study description (Wiley/Alzheimer\u2019s & Dementia) summarizing the Phase 2 trial design for AL002 in early AD. \ue200cite\ue202turn0search5\ue201",
        "- Alector announcement of INVOKE\u20112 Phase 2 results noting sustained target engagement and PD responses indicative of microglial activation (context for mechanism). \ue200cite\ue202turn0search3\ue201"
    ]
}